TMAO
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- TMAO is the first proven mechanistic link between gut bacteria and cardiovascular disease. Before TMAO, the connection between gut microbiome composition and cardiovascular risk was epidemiological. TMAO provides a specific, testable molecule with a defined pathway — from diet to gut bacteria to liver to artery — that explains part of why gut health matters for the heart.
- TMAO levels are largely determined by gut microbiome composition, not just diet. Two people eating the same meal can have dramatically different TMAO responses depending on which gut bacteria they harbor. Vegans and vegetarians typically have negligible TMAO production from dietary choline because their gut microbiomes lack the TMA-producing bacteria — demonstrating that the bacteria, not just the food, are the primary driver.
- Fish temporarily raises TMAO but the implications may differ. Fish contains pre-formed TMAO directly (fish use TMAO as an osmolyte), which raises blood TMAO acutely after consumption. The cardiovascular implications of fish-derived TMAO appear to differ from microbiome-derived TMAO — fish consumption is associated with lower cardiovascular risk despite transiently raising TMAO, possibly because fish also contains beneficial EPA/DHA and other compounds. If testing TMAO, avoid fish for 48 hours before the test for an accurate baseline.
- Mediterranean and plant-rich diets are associated with lower TMAO. These dietary patterns reduce the abundance of TMA-producing gut bacteria while promoting beneficial bacteria, shifting the microbiome away from high TMAO production even with moderate animal food consumption.
- TMAO and kidney function are tightly linked. TMAO is cleared by the kidneys; declining GFR causes TMAO accumulation independent of production rate. Elevated TMAO in the context of impaired kidney function (elevated cystatin C or creatinine) reflects both microbiome-mediated production and reduced clearance — and the cardiovascular risk implications may be compounded.
How Your Gut Bacteria Are Shaping Your Heart Attack Risk
The gut microbiome has attracted enormous scientific and popular attention over the past decade. But much of the coverage has focused on digestive symptoms, mood, and immune function — areas where the evidence is real but often diffuse and difficult to translate into specific, testable clinical metrics.
TMAO is different. It is a specific, measurable molecule with a defined pathway from the gut microbiome to cardiovascular disease, validated in prospective human studies. It was the first direct mechanistic link established between gut bacterial metabolism and atherosclerosis — a discovery that won the Cleveland Clinic's Stanley Hazen the inaugural Breakthrough Prize in Life Sciences recognition for clinical cardiovascular research.
The landmark 2013 paper in Nature Medicine — following earlier foundational work in Nature — demonstrated that TMAO predicted major cardiovascular events (heart attack, stroke, death) in a prospective study of 4,007 patients undergoing elective cardiac evaluation, with individuals in the highest TMAO quartile having a 2.5× higher event rate than those in the lowest quartile after adjustment for conventional risk factors. 1
The Pathway: From Steak to Artery
The TMAO pathway is one of the most clearly characterized gut-microbiome-to-disease mechanisms in human biology. Understanding it step by step clarifies both why it matters and how to intervene.
Step 1 — Dietary precursors: Foods rich in choline (eggs, red meat, liver, fish), phosphatidylcholine (lecithin), and L-carnitine (red meat) are consumed. These compounds reach the gut where they encounter the resident microbial community.
Step 2 — Bacterial TMA production: Specific gut bacteria — primarily from the genera Clostridium, Desulfovibrio, and Prevotella — express TMA lyase, an enzyme that cleaves choline and carnitine into trimethylamine (TMA). This step is microbiome-dependent: people lacking these bacteria produce negligible TMA regardless of dietary intake.
Step 3 — Hepatic oxidation to TMAO: TMA is absorbed from the colon into the portal circulation and reaches the liver, where the enzyme FMO3 oxidizes it to TMAO. FMO3 activity varies among individuals due to genetic polymorphisms — a second source of inter-individual TMAO variability beyond microbiome composition.
Step 4 — Circulation and excretion: TMAO enters the systemic circulation, where it acts on arterial walls, platelets, and cholesterol transporters, before being cleared by the kidneys.
| Level | Range | Interpretation | Notes |
|---|---|---|---|
| Optimal | < 3 µM | Low cardiovascular risk from TMAO pathway | Lowest quartile; associated with lowest event rates |
| Acceptable | 3–6 µM | Normal range | Within standard reference range; consider dietary and microbiome optimization |
| Elevated | 6–10 µM | Above optimal — intervention warranted | Dietary modification, microbiome-targeted strategies; avoid fish for 48h before retest |
| High | > 10 µM | Significantly elevated | Aggressive dietary and microbiome intervention; evaluate kidney function |
Already have your lab results? See how your TMAO and other markers score on a longevity scale — in under 60 seconds.
Analyze My Biomarkers →TMAO and Kidney Function: A Critical Interaction
One of the most important clinical nuances of TMAO is its relationship with kidney function. TMAO is renally cleared — the kidneys filter it from the blood and excrete it in urine. As GFR declines, TMAO clearance falls and circulating TMAO rises, independent of production rate.
This creates a compounding problem in kidney disease: impaired kidney function both accumulates TMAO (due to reduced clearance) and is itself associated with gut dysbiosis that increases TMAO production. Patients with chronic kidney disease consistently have TMAO levels 5–10× higher than those with normal kidney function, and TMAO is thought to contribute to the cardiovascular mortality that is the leading cause of death in CKD.
For longevity assessment purposes, TMAO interpretation should always be contextualized with kidney function markers (cystatin C, creatinine-based eGFR). Elevated TMAO in a person with impaired kidney function is a compounded risk signal — both the microbiome-mediated TMAO production and the impaired clearance contribute to the elevation, and both the cardiovascular and renal risks are additive.
Sources
- Tang WHW, et al. "Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk." New England Journal of Medicine, 2013. PubMed →
| Range Type | Value (µM) | Notes |
|---|---|---|
| Standard Clinical Range | < 6 µM | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | < 3 µM |
Associated with reduced all-cause mortality and extended healthspan.
Reference ranges for TMAO vary by laboratory and assay method. The key finding from prospective studies is a dose-response relationship — each increment in TMAO is associated with proportionally higher cardiovascular risk, with the sharpest inflections above 5–6 µM. Longevity-focused practitioners target the lowest quartile of population distribution, generally below 3 µM. Importantly, TMAO interpretation should account for fish consumption: fish is high in pre-formed TMAO (as well as TMAO precursors), so high fish intake transiently elevates TMAO without the same cardiovascular risk implications as gut-bacteria-produced TMAO from red meat and eggs.
|
Already have your results? See what your TMAO and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
How was TMAO discovered to be a cardiovascular risk factor?
The TMAO story began in 2011 when Stanley Hazen's group at the Cleveland Clinic was studying metabolites that differed between people who went on to have cardiovascular events and those who didn't. Using an untargeted metabolomics approach — measuring thousands of metabolites simultaneously without a predetermined hypothesis — they identified TMAO as one of the most discriminating metabolites. Critically, they then traced its origin: TMAO came from gut bacteria metabolizing dietary phosphatidylcholine (from eggs and red meat). They demonstrated in animal models that colonizing mice with TMAO-producing bacteria and feeding them high-choline diets accelerated atherosclerosis, and that suppressing gut bacterial TMA production with an antibiotic reduced atherosclerosis. This was the first direct demonstration that gut bacteria contributed to atherosclerosis through a specific, identifiable metabolic pathway.
Does eating red meat and eggs always raise TMAO?
No — and this is one of the most important nuances of TMAO biology. TMAO production from dietary choline and carnitine is almost entirely determined by the gut microbiome. People who lack TMA-producing bacteria (common in vegans and vegetarians who have never consumed these foods and therefore never developed the relevant bacterial populations) produce negligible TMAO even after consuming large amounts of red meat or eggs. People with established TMA-producing bacterial communities (common in habitual red meat consumers) convert a significant fraction of dietary choline and carnitine to TMA and subsequently TMAO. This means two people eating identical diets can have TMAO levels that differ by 10-fold or more. The gut microbiome is the critical variable — not simply the food consumed.
Can I lower my TMAO without changing my diet?
Potentially — though the evidence is still emerging. Strategies targeting the gut microbiome directly include: probiotic supplementation with Lactobacillus and Bifidobacterium species (which generally do not produce TMA and may competitively reduce TMA-producers); prebiotic fiber consumption (which feeds beneficial bacteria and shifts the microbiome away from TMA-producing species); and fermented foods. 3,3-Dimethyl-1-butanol (DMB), a naturally occurring compound found in cold-pressed olive oil, balsamic vinegar, and certain wines, inhibits bacterial TMA lyase — the enzyme TMA-producing bacteria use — and has been shown to reduce TMAO in animal models. Direct FMO3 inhibitors are being explored as pharmaceutical targets. In practice, the combination of dietary changes and microbiome-targeted strategies is currently more evidence-based than microbiome intervention alone.
Is TMAO the reason red meat is associated with cardiovascular risk?
TMAO is one proposed mechanism, but not the only one and probably not the entire explanation. Red meat's cardiovascular implications are multifactorial: it contains saturated fat that raises LDL and ApoB; it contains heme iron that may promote oxidative stress; it may displace plant foods with cardiovascular-protective properties; and through TMAO, it introduces a gut-microbiome-mediated pathway to atherosclerosis. The relative contribution of each mechanism is debated. What is notable is that unprocessed red meat has substantially weaker associations with cardiovascular disease than processed meat (bacon, sausage, hot dogs) in epidemiological studies — suggesting that processing-related factors (sodium, nitrates, heme iron concentration) may be more important cardiovascular drivers than TMAO alone.
How does TMAO promote atherosclerosis mechanistically?
Several mechanisms have been identified in animal studies and human cell work. TMAO inhibits reverse cholesterol transport — the process by which HDL extracts cholesterol from arterial walls — by downregulating key bile acid synthetic enzymes and transporters, effectively reducing the liver's ability to excrete cholesterol. TMAO promotes macrophage transformation into foam cells — the lipid-laden macrophages that are the cellular building blocks of atherosclerotic plaques — by upregulating scavenger receptors on macrophages. TMAO enhances platelet reactivity and thrombosis by acting on platelet receptors, increasing the tendency to form clots when a plaque ruptures. TMAO promotes endothelial dysfunction by increasing inflammatory signaling in the cells lining arteries. Together these mechanisms explain why TMAO predicts both atherosclerotic progression and thrombotic events — it simultaneously accelerates plaque formation and increases the likelihood that a plaque will precipitate an acute event.